

Presentation to the FDA and Anesthesiology and Respiratory Therapy Devices Panel In advance of virtual public meeting: February 2, 2024



Nirav Bhakta, MD, PhD

Vice-Chair of the **American Thoracic Society** Pulmonary Function Testing Committee
Recent co-chair of ATS Workshop and Statement on Race in Pulmonary Function Testing

Associate Professor

Associate Director, Adult Pulmonary Function Laboratory
Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine
University of California, San Francisco



Disclosure slide

- *I have NO financial disclosure or conflicts of interest with the presented material in this presentation*



Remove bias from pulse oximetry to: Minimize doubt and address health-care disparities

1. Medical devices should be authorized based on evidence from high quality studies showing devices provide accurate and reliable readings.




Remove bias from pulse oximetry to: Minimize doubt and address health-care disparities

1. Medical devices should be authorized based on evidence from high quality studies showing devices provide accurate and reliable readings.



Transparent bias limits across the SpO₂ range tested plus standards for precision



Fawzy et al.
JAMA Internal Medicine 2022



Remove bias from pulse oximetry to: Minimize doubt and address health-care disparities

1. Medical devices should be authorized based on evidence from high quality studies showing devices provide accurate and reliable readings.
2. The evidence submitted to support authorization of medical devices should be based on data collected from large and diverse study populations representative of the patients we take care of. Diversity needs to include diversity in skin tones, race and ethnicity, and clinical situations including states of low perfusion as is common in critical illness.



Remove bias from pulse oximetry to: Minimize doubt and address health-care disparities

1. Medical devices should be authorized based on evidence from high quality studies showing devices provide accurate and reliable readings.
2. The evidence submitted to support authorization of medical devices should be based on data collected from large and diverse study populations representative of the patients we take care of. Diversity needs to include diversity in skin tones, race and ethnicity, and clinical situations including states of low perfusion as is common in critical illness.
3. There should be greater transparency with respect to the evidence submitted to support authorization.




Remove bias from pulse oximetry to: Minimize doubt and address health-care disparities


1. Medical devices should be authorized based on evidence from high quality studies showing devices provide accurate and reliable readings.
2. The evidence submitted to support authorization of medical devices should be based on data collected from large and diverse study populations representative of the patients we take care of. Diversity needs to include diversity in skin tones, race and ethnicity, and clinical situations including states of low perfusion as is common in critical illness.
3. There should be greater transparency with respect to the evidence submitted to support authorization.
4. There is a need for ongoing post-marketing real-world studies.



Importance of real-world data and feedback from the front-line



MAUDE - Manufacturer and User Facility Device Experience




Remove bias from pulse oximetry to: Minimize doubt and address health-care disparities

1. Medical devices should be authorized based on evidence from high quality studies showing devices provide accurate and reliable readings.
2. The evidence submitted to support authorization of medical devices should be based on data collected from large and diverse study populations representative of the patients we take care of. Diversity needs to include diversity in skin tones, race and ethnicity, and clinical situations including states of low perfusion as is common in critical illness.
3. There should be greater transparency with respect to the evidence submitted to support authorization.
4. There is a need for ongoing post-marketing evaluation including real-world studies.
5. There is a need to regulate pulse oximeters sold directly to consumers.



Improve consumer-grade pulse oximeters



Google image search "consumer pulse oximeters" 1/11/24



THANK YOU FOR INVITING THE ATS

1. Medical devices should be authorized based on evidence from high quality studies showing devices provide accurate and reliable readings.
2. The evidence submitted to support authorization of medical devices should be based on data collected from large and diverse study populations representative of the patients we take care of. Diversity needs to include diversity in skin tones, race and ethnicity, and clinical situations including states of low perfusion as is common in critical illness.
3. There should be greater transparency with respect to the evidence submitted to support authorization.
4. There is a need for ongoing post-marketing evaluation including real-world studies.
5. There is a need to regulate pulse oximeters sold directly to consumers.

